119190-36-2Relevant articles and documents
Method of treatment for prostatic cancer
-
, (2008/06/13)
Disclosed is a new treatment for men with prostatic cancer involving combination therapy of a 5α-reductase inhibitor, i.e., a 17β-substituted 4-azasteroid, a 17β-substituted non-azasteroid, 17β-acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an antiandrogen, i.e. flutamide. Pharmaceutical compositions useful for treatment are also disclosed.
Method of treatment for benign prostatic hyperplasia
-
, (2008/06/13)
Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5α-reductase inhibitor, e.g. a 17β-substituted 4-azasteroid, a 17β-substituted non-azasteroid, 17β-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an α1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.
Steriod 5-alpha-reductase inhibitors
-
, (2008/06/13)
Invented are substituted acrylate analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds to inhibit steroid 5-α-reductase. Also invented are intermediates used in preparing these compounds.
Steroid 5-alpha-reductase inhibitors
-
, (2008/06/13)
[From equivalent EP0289327A3] Compounds of formula (I) : ψψ in which, inter alia, R± is H or C±±±alkyl and M is O or S, processes for their preparation, pharmaceutical compositions containing then and their use as inhibitors of 5-à-reductase in the treatment in the reduction of prostate size.ψ
Inhibition of Steroid 5α-Reductase by Unsaturated 3-Carboxysteroids
Holt, Dennis A.,Levy, Mark A.,Oh, Hye-Ja,Erb, Jill M.,Heaslip, Julie I.,et al.
, p. 943 - 950 (2007/10/02)
A series of unsaturated steroids bearing a 3-carboxy substituent has been prepared and assayed in vitro as inhibitors of human and rat prostatic steroid 5α-reductase (EC 1.3.1.30).It is proposed that the observed tight binding of the 3-androstene-3-carboxylic acids is due to mimicry of a putative, high-energy, enzyme-bound enolate intermediate formed during the NADPH-dependent conjugate reduction of testosterone by steroid 5α-reductase.These compounds were prepared through palladium(0)-catalyzed carbomethoxylations of enol (trifluoromethyl)sulfonates derived from 3-keto precursors.Modification of A and B ring unsaturation and substitution at C-3, -4, -6, and -11 was explored.Mono- and dialkylcarboxamides were employed as 17β side chains to enhance inhibitory activity with the human enzyme.
STEROID 5-ALPHA-REDUCTASE INHIBITORS
-
, (2008/06/13)
Invented are substituted acrylate analogues of steroidal synthetic compounds, pharmaceutical compositions containing the compounds, and methods of using these compounds to inhibit steroid 5-alpha-reductase. Also invented are intermediates used in preparing these compounds
